Last $6.30 USD
Change Today +0.28 / 4.65%
Volume 51.0K
TRVN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

trevena inc (TRVN) Snapshot

Open
$6.01
Previous Close
$6.02
Day High
$6.46
Day Low
$5.90
52 Week High
03/5/14 - $9.95
52 Week Low
06/18/14 - $4.07
Market Cap
166.1M
Average Volume 10 Days
191.8K
EPS TTM
--
Shares Outstanding
26.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TREVENA INC (TRVN)

Related News

No related news articles were found.

trevena inc (TRVN) Related Businessweek News

No Related Businessweek News Found

trevena inc (TRVN) Details

Trevena, Inc., a clinical stage biopharmaceutical company, discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors. The company is developing TRV027 that is in Phase IIb clinical trial for the treatment of acute heart failure; TRV130, which has completed Phase Ib clinical trial for the treatment of moderate to severe acute pain intravenously; and TRV734 that is in Phase I clinical trial as an orally administered treatment for moderate to severe acute and chronic pain. It also focuses on the discovery of an orally bioavailable, small molecule d-opioid receptor G protein biased ligand for the treatment of central nervous system disorders. The company was formerly known as Parallax Therapeutics, Inc. and changed its name to Trevena, Inc. in January 2008. Trevena, Inc. was founded in 2007 and is based in King of Prussia, Pennsylvania.

32 Employees
Last Reported Date: 03/20/14
Founded in 2007

trevena inc (TRVN) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $532.6K
Senior Vice President of Clinical Development
Total Annual Compensation: $376.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $441.4K
Compensation as of Fiscal Year 2013.

trevena inc (TRVN) Key Developments

Trevena, Inc. Announces Board Changes

Trevena, Inc. announced that Julie H. McHugh, former president of Centocor and chief operating officer at Endo Health Solutions, and Barbara Yanni, former chief licensing officer at Merck & Co., have joined Trevena's board of directors. The two directors replace Terrance G. McGuire and David F. Solomon who are stepping down from the board following the company's recent initial public offering. Most recently Ms. McHugh served as chief operating officer at Endo Health Solutions Inc. from 2010 to 2013. Ms. Yanni had a 28-year career at Merck & Co., Inc., where she was vice president and chief licensing officer before her retirement in March 2014.

Trevena, Inc.(NasdaqGS:TRVN) dropped from Russell 2000 Index

Trevena, Inc. will be removed from the Russell 2000 Index.

Trevena, Inc.(NasdaqGS:TRVN) dropped from Russell 3000 Index

Trevena, Inc. will be removed from the Russell 3000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRVN:US $6.30 USD +0.28

TRVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TRVN.
View Industry Companies
 

Industry Analysis

TRVN

Industry Average

Valuation TRVN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,076.4x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 795.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TREVENA INC, please visit www.trevenainc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.